Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
After one month, the Bitcoin Ahr999 Index has once again entered the "buy-the-dip zone"

After one month, the Bitcoin Ahr999 Index has once again entered the "buy-the-dip zone"

BlockBeatsBlockBeats2026/05/29 03:39
Show original

BlockBeats news, on May 29, according to information from a third-party data platform, Bitcoin Ahr999 fell below 0.45 again after a month, currently at 0.4322. As a result, this indicator has once again fallen back into the "bottom fishing range".


This indicator was created by ahr999 and aims to assist Bitcoin dollar-cost averaging users in making investment decisions combined with timing strategies. This indicator implies the short-term dollar-cost averaging yield of Bitcoin and the degree of deviation of the Bitcoin price from its expected valuation.


In Bitcoin’s history, the Ahr999 index has been below the bottom fishing line (0.45) for 572 days. The dollar-cost averaging range is 0.45-1.2, which means the Bitcoin price is in a relatively reasonable range, suitable for maintaining a regular investment strategy.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53